Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CEL-SCI Corporation (NYSE American: CVM) SEC filings, offering detailed insight into the company’s clinical stage cancer immunotherapy business and capital structure. As a Colorado corporation filing under Commission file number 001-11889, CEL-SCI uses periodic and current reports to describe its development of Multikine (Leukocyte Interleukin, Injection), financing activities, and corporate governance arrangements.
Investors can review Form 10-K and Form 10-Q filings for discussions of research and development expenses, going concern disclosures, and updates on the Multikine clinical program in head and neck cancer. These reports typically describe the company’s strategy of boosting the immune system before surgery, radiotherapy and chemotherapy have damaged it, and summarize the status of the completed Phase 3 study and planned 212-patient confirmatory Registration Study.
Form 8-K current reports are particularly important for CEL-SCI. Recent 8-K filings disclose material definitive agreements for best-efforts public offerings of common stock with ThinkEquity LLC as placement agent, including the number of shares issued, offering prices, gross proceeds, and intended use of proceeds to fund the continued development of Multikine, general corporate purposes, and working capital. Other 8-Ks report amendments and revisions to the company’s Shareholder Rights Agreement, including extensions of its expiration date and related governance terms.
Users can also reference registration statements on Form S-3 cited in these filings, which support CEL-SCI’s shelf offerings. Together, these documents help clarify how the company finances its operations, manages shareholder rights, and describes the risks associated with its clinical stage status, including going concern language noted by its independent auditors. Stock Titan’s tools can surface the most relevant sections, summarize lengthy filings, and make it easier to track new CVM filings as they are posted to EDGAR, including any future Forms 4 reporting insider transactions.
Form 4 filed for CEL-SCI Corp (CVM) discloses that the reporting person, identified as an officer with the title Chief Scientific Officer, executed a purchase on 09/30/2025. The report shows an acquisition of 260 shares of Common Stock at a price of $9.20 per share, resulting in 5,808 shares beneficially owned following the transaction. The Form is signed by the reporting person on 10/02/2025.
Patricia Prichep, Chief Financial Officer of CEL-SCI Corporation (CVM), reported an open-market purchase of company common stock. On 09/30/2025 she acquired 466 shares at a reported price of $9.20 per share. After this transaction she beneficially owns 11,213 shares directly. The filing is a Form 4 statement of changes in beneficial ownership and is signed by Ms. Prichep on 10/02/2025. The report identifies her relationship to the issuer as an officer with the title Chief Financial Officer.
Geert Kersten, listed as Chief Executive Officer and a director of CEL-SCI Corporation (CVM), reported an open-market purchase of 570 shares of CEL-SCI common stock on 09/30/2025 at a price of $9.20 per share. After this transaction the filing shows 73,405 shares beneficially owned directly. The Form 4 was signed on 10/02/2025. The report contains no derivative transactions and includes no additional explanatory disclosures.
CEL-SCI Corporation filed a registration statement on Form S-8 to register securities for issuance under its 2025 Non-Qualified Stock Option Plan and 2025 Stock Bonus Plan. These plans are designed to grant stock options and stock awards to eligible participants, with detailed plan terms provided in a separate prospectus cross-referenced in the filing.
The company incorporates by reference its most recent Annual Report on Form 10-K, quarterly reports on Form 10-Q, several current reports on Form 8-K, and its proxy statement, so that investors can rely on those disclosures when securities are offered under the plans. The filing also describes indemnification provisions for directors and officers under Colorado law, standard SEC undertakings about future amendments and filings, and includes a power of attorney and signatures from senior officers and directors authorizing the registration.
CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC for a registered direct offering of 1,111,200 shares of common stock at $9.00 per share. The offering closed on August 29, 2025, generating gross proceeds of approximately $10,000,800 before fees and expenses. CEL-SCI plans to use the net proceeds to continue developing its Multikine program, as well as for general corporate purposes and working capital.
The company will pay the placement agent a 7.0% cash fee on gross proceeds and reimburse certain expenses up to $185,000. For 30 days after closing, CEL-SCI agreed not to issue or register additional equity securities, subject to exceptions, and its directors and officers agreed to 45-day lock-ups on sales or transfers of company securities. The shares were sold under an effective Form S-3 shelf registration and related prospectus supplement.
Lincoln Alternative Strategies LLC reported beneficial ownership of 555,000 shares of CEL-SCI Corporation common stock, representing 6.94% of the outstanding class. The filing states the reporter is organized in Delaware and holds sole voting and dispositive power over these shares. The report also includes a certification that the shares were not acquired to change or influence control of the issuer and are not held in connection with such transactions. The disclosure identifies the position as passive ownership under the Schedule 13G framework and provides the reporter's signature by its managing member.
Cel-Sci (CVM) prospectus supplement excerpt reports clinical outcomes from a trial with dates noted: June 30, 2025 and August 22, 2025. The results state no lymph node involvement by PET imaging and low PD-L1 tumor expression (TPS <10) on biopsy. Treated patients showed a 0.349 hazard ratio for death versus control (95% CI [0.18, 0.66], Wald p=0.0012), representing a 28.6% absolute 5-year overall survival benefit versus control (p=0.0015) and a stated risk-of-death reduction of about one-half at five years. The data also report greater than 35% rates of pre-surgery tumor reductions and/or downstages (p<0.01). The excerpt contrasts the low PD-L1 context with settings where Keytruda and Opdivo work best (high PD-L1).
Cel-Sci Corporation (CVM) prospectus supplement excerpt highlights clinical and securities details. The text states the company’s product candidates are intended to be given immediately after diagnosis and before any other treatment, including surgery. Clinical outcomes cited include a reduction in risk of death by half at five years versus control, a 28.6% absolute 5-year overall survival benefit (p=0.0015), and a hazard ratio of 0.349 versus control with 95% CIs [0.18, 0.66] (Wald p=0.0012). The excerpt also reports a >35% rate of pre-surgery tumor reductions and/or downstages (p<0.01) and notes activity in tumors with low PD-L1 expression (TPS <10), where some checkpoint inhibitors are less effective.
The filing excerpt discloses that 546,894 shares of common stock are issuable upon exercise of outstanding stock options as of June 30, 2025, at a weighted average exercise price of $195.06 per share. The text includes dates (June 30, 2025; August 22, 2025) and a Bloomberg market reference link but does not provide offering size, proceeds, or complete prospectus financial tables in this excerpt.
Cel‑Sci Corporation (CVM) reported unaudited results for the quarterly period ended June 30, 2025. Total assets were $20.34 million versus $26.99 million a year earlier, driven by a cash decline to $1.79 million from $4.74 million. The company recorded a nine‑month net loss of $19.31 million compared to $20.81 million in the prior year; research and development expense was $12.18 million and general and administrative expense was $6.59 million. Cash used in operating activities totaled $12.45 million while proceeds from issuance of common stock and pre‑funded warrants were $12.56 million during the period. Management discloses substantial doubt about the company’s ability to continue as a going concern and estimates about $30 million will be required to finance the planned 212‑patient confirmatory Multikine study. A 30‑for‑1 reverse stock split became effective in May 2025 and shares outstanding were 5,321,341 at June 30, 2025. Subsequent to period end the company sold 1,500,000 shares for approximately $5.7 million.
CEL-SCI Corporation (NYSE American: CVM) has filed Amendment No. 1 to a Form S-3 shelf registration, enabling the company to issue up to $100 million of common stock, preferred stock (including convertibles), rights, warrants and/or units on a continuous basis. Pricing, size, and underwriter details will be set in future prospectus supplements.
The document retroactively reflects the 1-for-30 reverse stock split effected 20 May 2025, which cut outstanding shares from roughly 94 million to about 3.1 million while leaving authorised share counts unchanged. CEL-SCI lists 6,882,156 post-split shares outstanding as of 4 Aug 2025; the stock last closed at $9.25.
Net proceeds are earmarked primarily to advance lead immunotherapy Multikine®. In a Phase III trial’s target subgroup (no nodal involvement; low PD-L1) Multikine delivered 73 % 5-year survival versus 45 % for standard of care (hazard ratio 0.35). The FDA has cleared a 212-patient confirmatory registration study, potentially allowing an accelerated approval filing once fully enrolled.
CEL-SCI is a late-stage biotech with no product approvals or revenue. FY-2024 net loss was $27.6 million and the auditor flagged going-concern risk. Management warns that the contemplated securities are high-risk and potentially dilutive; proceeds are needed to fund trials, operations and working capital.